Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Non-Randomized, Open-Label, Three-Part, Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, and Quinidine on the Pharmacokinetics and Safety of EDP-514 in Healthy Subjects

NCT04783753 is registered in ClinicalTrials.gov with Enanta Pharmaceuticals, Inc as lead sponsor.

NCT NCT04783753
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04783753 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Non-Randomized, Open-Label, Three-Part, Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, and Quinidine on the Pharmacokinetics and Safety of EDP-514 in Healthy Subjects
Lead sponsor
Enanta Pharmaceuticals, Inc
Phase
Phase 1
Overall status
Completed
Start date
November 5, 2020
Completion date
July 9, 2021
Enrollment
72 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis b